Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data

Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. Early this morning, gene therapy focused biopharmaceutical company IVERIC bio Inc. (I...
Streetwise Reports | October 29, 2019 |

Acceleron Shares Open 50% Higher on Phase 2 PAH Trial Data

Acceleron Pharma's shares established a new 52-week high after the company reported that sotatercept achieved both primary and secondary endpoints in the Phase 2 PULSAR study in patients with pulmonary arterial hypertension. After U.S. markets closed for trading ye...
Streetwise Reports | January 29, 2020 |

T2 Biosystems Shares Nearly Double on Worldwide COVID-19 Testing License Deal

Shares of T2 Biosystems Inc. traded 90% higher after the company reported that a new COVID-19 assay licensed from Hackensack Meridian Health's Center for Discovery and Innovation will be adapted to run on its FDA-cleared T2Dx® Instrument. Diagnostic...
Streetwise Reports | March 26, 2020 |

The world’s next high-grade copper mine is nearing construction

The following is a transcription of the above video, and The Market Online Canada has edited it for clarity . Adventus Mining Corp. (TSXV:ADZN) continues to be focused on its El Domo project, a copper-gold project in Ecuador. The company is swiftly moving forward, ...
Brieanna McCutcheon | February 12, 2024 |

Top Pick Status Given to Small-Cap with Pain Drug Candidate

The primary reason for the rating—upcoming trial results—is discussed in an Echelon Wealth Partners report. In a July 10 research note, analyst Douglas Loe reported that Echelon Wealth Partners bestowed Top Pick status on Antibe Therapeutics Inc. (ATE:TSX.V...
Streetwise Reports | July 19, 2019 |

Shares Rise as The Medicines Company Reports Positive Topline Results...

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hype...
Streetwise Reports | September 26, 2019 |

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a N...
Streetwise Reports | November 20, 2019 |

Biopharma's Phase 3 Trial Results in Migraine 'Robust,' 'Impressive'

These topline data and next steps for the therapeutic are reviewed in a Ladenburg Thalmann report. In a Dec. 30 research note, analyst Matthew Kaplan reported that Ladenburg Thalmann increased its price target on Buy-rated Axsome Therapeutics Inc. (AXSM:NASDAQ) to $...
Streetwise Reports | January 6, 2020 |

Apellis Pharma Shares Rise 20% on Positive Top-line Data in Phase 3 PNH Trial

Shares of Apellis Pharmaceuticals opened 35% higher and established a new 52-week intraday high price today after the company announced positive top-line results from its Phase 3 head-to-head study of Pegcetacoplan (APL-2) versus Eculizumab in patients with Paroxysmal Nocturna...
Streetwise Reports | January 8, 2020 |

Insmed Shares Trade 40% Higher on Phase 2 Top-Line Bronchiectasis Trial Data

Insmed Inc.'s shares traded higher today after the company reported positive top-line results from its Phase 2 WILLOW Study of INS1007 in patients with non-cystic fibrosis bronchiectasis. Global biopharmaceutical company Insmed Inc. (INSM:NASDAQ) , which is...
Streetwise Reports | February 4, 2020 |
1 2 3 4 5 6 7 8 9 10 ...